Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Precision Biosciences (DTIL) Short term Debt (2021 - 2024)

Precision Biosciences (DTIL) has disclosed Short term Debt for 3 consecutive years, with $22.5 million as the latest value for Q2 2024.

  • On a quarterly basis, Short term Debt rose 0.79% to $22.5 million in Q2 2024 year-over-year; TTM through Jun 2024 was $22.5 million, a 0.79% increase, with the full-year FY2023 number at $22.4 million, changed N/A from a year prior.
  • Short term Debt was $22.5 million for Q2 2024 at Precision Biosciences, roughly flat from $22.5 million in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $22.5 million in Q2 2024 to a low of $2.4 million in Q2 2021.
  • A 3-year average of $16.7 million and a median of $22.4 million in 2023 define the central range for Short term Debt.
  • Biggest YoY gain for Short term Debt was 0.79% in 2024; the steepest drop was 0.79% in 2024.
  • Precision Biosciences' Short term Debt stood at $2.5 million in 2021, then surged by 813.28% to $22.4 million in 2023, then increased by 0.37% to $22.5 million in 2024.
  • Per Business Quant, the three most recent readings for DTIL's Short term Debt are $22.5 million (Q2 2024), $22.5 million (Q1 2024), and $22.4 million (Q4 2023).